Stability-Indicating Method For The Determination Of N-Desmethyldiazepam And Simultaneous Determination Of Its Degradation Products

Abstract

A simple, direct and sensitive spectrophotometric method for the determination of the intact N-desmethyldiazepam in the presence of its degradation products, 2-amino-5-chlorobenzophenone and glycine, is developed. The proposed procedure is based on direct measurement of the absorbance of its acidified methanolic solution at 361 nm. The procedure determines 8–56 mcg ml^?1 of N-desmethyldiazepam with an accuracy of 100.2 ± 0.51%. The proposed procedure retains its accuracy in presence of up to 80% of the different degradation products. The procedure is applied successfully for the determination of N-desmethyldiazepam in bulk powder, tablets and drops.

Simultaneous determination of the different degradation products in the presence of the parent drug is also described. Thus, 2-amino-5-chlorobenzophenone is determined by direct measurement of its methanolic solution at about 380 nm, with an accuracy of 100.4 ± 0.42%. Glycine is determined colorimetrically using ninhydrin reagent in presence of pyridine, with an accuracy of 99.5 ± 0.78%.     

Stability-Indicating High Performance liquid Chromatographic Determination of Diltiazem Hydrochloride

Abstract

A rapid, selective and accurate high-performance liquid chromatography method (HPLC) for the determination of diltiazem hydrochloride using clonazepam as internal standard is developed. The investigated compounds were eluted from 5 u Micropak MCH-5 reversed phase column at ambient temperature with a mobile phase comprising of acetonitrile-water (48:52%) at pH 3.3 and containing 0. 01M sodium-n-octane sulfonate as an ion pairing substance. The mobile phase was pumped at a flow rate of 1 ml min^?1 and the effluent was monitored at 239 nm. The retention times of the internal standard and diltiazem were at 3 min and 9 min, respectively. A linear relationship was derived between the peak height ratio (diltiazem/clonazepam) and diltiazem concentration over the range 1–10 μg ml^?1. Detection limit for the drug is 0.2 μg ml^?1 at 0.01 aufs. The developed procedure was applied to study the stability of diltiazem in the presence of its degradation products as well as in the presence of formulation excipients.     

Reversed-Phase High Performance Liquid Chromatographic and Thin Layer Chromatographic Methods for the Simultaneous Determination of Benazepril Hydrochloride and Hydrochlorothiazide in Cibadrex Tablets

ABSTRACT

Two procedures were developed for simultaneous determination of benazepril hydrochloride (I) and hydrochlorothiazide (II) in pure, laboratory made mixtures and in pharmaceutical dosage form “Cibadrex tablets® using reversed phase high performance liquid chromatographic and thin layer chromatographic methods.

For reversed phase HPLC, a new very sensitive, rapid, selective method was developed. The linearity ranges were 32-448 ng/20 μl and 40-560 ng/20 μl for benazepril hydrochloride and hydrochlorothiazide, respectively. The corresponding recoveries were 99.38 ± 1.526 and 99.2 ± 1.123.

The minimum detection limits were 7 ng/20 μl and 14 ng/20 μl for benazepril hydrochloride and hydrochlorothiazide respectively.

On the other hand, a new, simple, sensitive and fast thin layer chromatographic scanning densitometric method was developed for simultaneous determination of benazepril hydrochloride and hydrochlorothiazide using ethyl acetate: methanol: ammonia (85: 20: 10 v/v) as the developing system. The R_f values were 0.33 & 0.68 for benazepril hydrochloride and hydrochlorothiazide respectively. The minimum detection limit obtained was 0.12 μg/spot for benazepril hydrochloride and 0.24 μg/spot for hydrochlorothiazide. The mean percentage recoveries were 100.04 ± 1.102 and 99.31 ± 1.009 for benazepril hydrochloride and hydrochlorothiazide respectively.

The two proposed methods were simple, precise, sensitive and could be successfully applied for the determination of pure, laboratory made mixtures and pharmaceutical dosage forms. The results obtained were compared with those obtained by A ^1%.     

Utility of Derivative Spectrophotometry in the Determination of Carbochromen Hydrochloride and Dipyridamole in the Presence of Their Oxidative Degradation Products

Abstract

Direct spectrophotometric methods for the determination of carbochromen hydrochloride and dipyridamole, each in the presence of its oxidative degradation products, are presented. the methods are based on the first derivative (D₁) and second derivative (D₂) spectrophotometric measurement (absolute trough, U) at 336 nm and (Peak-trough, Y) at 309–342 nm for carbochromen hydrochloride and at 240–260 nm(U) and 246–268 nm(Y) for dipyridamole. Plots of D₁ or D₂ versus concentration were linear over the concentration range of 8.00–16.00 μg/ml for carbochromen hydrochloride and 4.00–12.00 μg/ml for dipyridamole. Oxidative degradation of these drugs has been optimized with respect to hydrogen peroxide concentration. Determining the intact in coexistence with its oxidative degradation product, the proposed derivative spectrophotometric methods proved to be of high potential in correcting the systematic error appearing in the results of the A_max method due to the latter. Assaying the commercial tablets, the proposed method gave results of high accuracy and reproducibility.     

High Pressure Liquid Chromatographic Determination of Promethazine Hydrochloride in the Presence of its Thermal and Photolytic Degradation Products: A Stability Indicating Assay

Abstract

A stability indicating method has been developed for the quantitation of promethazine hydrochloride in the presence of its photolytic and thermal degradation products. Following a basic extraction with acetonitrile, promethazine is separated from its internal standard, promazine, and vehicle components by direct high performance liquid chromatography using ultraviolet detection (249 nm) and a stainless steel column 25 cm in length, 0.46 cm i.d. packed with octa-decyl silica 5μ in diameter. A linear relationship was obtained between peak height ratio (promethazine/promazine) and promethazine hydrochloride in water over the range 30–600 g/ml. The percent coefficient of variation of the assay is 0.8% and the recovery of promethazine hydrochloride from aqueous solutions is 99.7%. The photolytic degradation of promethazine hydrochloride does not follow simple first order kinetics. Potassium iodide and p-benzoquinone had a significant effect on the degradation rate of promethazine during the first 30 minutes of the photolytic degradation reaction. However, after one hour there is no apparent quenching effect on the photolytic degradation rate of promethazine hydrochloride in the presence of these quenchers.     

Stability‐Indicating Methods for the Determination of Rofecoxib

Two stability indicating methods have been developed for determining rofecoxib in the presence of its degradation product. The first suggested method is high performance liquid chromatography (HPLC), in which analysis is carried out using hypersil BDS C18 column (250 × 4.6 mm I.D.) with mobile Phase consisting of 0.05 M phosphate buffer (pH 3.5) and acetonitrile (70:30 v/v). A linear relationship was obtained between the detector response at 225 nm and the corresponding concentration of the studied rofecoxib in the concentration range (1–6 μg / 10 μl) with mean % recovery of 99.80 ± 0.405. The second method depends on the quantitative densitometric evaluation of thin layer chromatograms (HPTLC) with mobil phase consisting of toluene: chloroform: methanol (60: 35: 5 v/v/v) by using fluorescent high performance silica gel 60 plate. A linear relationship was obtained between peak area and the concentration of the cited drug in the range 1–6 μg/spot with a mean % recovery of 99.79 ± 0.185. The suggested methods are precise, accurate, rapid and prove their specificity in the presence of its degradation products. Both procedures are successfully applied to determine the drug in the presence of its degradation product and also in their pharmaceutical formulations.     

Spectrophotometric Determination Of Rifampin in the Presence of its Degradation Products in Pharmaceutical Preparations

Abstract

The determination of rifampin in the presence of its main degradation products, 3-formyl rifampin and rifampin quinone using two spectrophotometric methods is described. Both Glenn's method and first derivative spectrophotometry were successfully adopted. No preliminary separation steps were required in either cases. Both methods gave accurate and reproducible results for the determination of the drug in dosage forms. The percentage recoveries ranged from 99.33% ±0.63 to 100.2% ± 0.44. The proposed methods are more simple, rapid than other existing methods and can be readily adopted in control laboratory.     

Kinetics and Characterization of Degradation Products of Dihydralazine and Hydrochlorothiazide in Binary Mixture by HPLC-UV,LC-DAD and LC–MS Methods

Dihydralazine and hydrochlorothiazide were stored at high temperature and humidity, under UV/Vis light and different pH, as individual drugs and the mixture. Then, a sensitive and selective HPLC-UV method was developed for simultaneous determination of dihydralazine and hydrochlorothiazide in presence of their degradation products. Finally, the degradation products were characterized through LC-DAD and LC–MS methods. Dihydralazine was sensitive to high temperature and humidity, UV/Vis light and pH?≥?7. At the same time, it was resistant to acidic conditions. Hydrochlorothiazide was sensitive to high temperature and humidity, UV/Vis light and changes in pH. Its highest level of degradation was observed in 1 M HCl. Degradation of the drugs was higher when they were stressed in the mixture. In the case of dihydralazine, the percentage degradation was 5–15 times higher. What is more, dihydralazine became sensitive to acidic conditions. Hydrochlorothiazide was shown to be more sensitive to UV/Vis light and pH?>?4. Degradation of dihydralazine and hydrochlorothiazide followed first-order kinetics. The quickest degradation of dihydralazine was found to be in 1 M NaOH while of hydrochlorothiazide was in 1 M HCl (individual hydrochlorothiazide) or at pH 7–10 (hydrochlorothiazide in the mixture). A number of new degradation products were detected and some of them were identified by our LC-DAD and LC–MS methods. In the stressed individual samples, (phenylmethyl)hydrazine and 1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide were observed for the first time. Interactions between dihydralazine and hydrochlorothiazide in the mixture were confirmed by additional degradation products, e.g., 2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1,4-trioxide.     

Development and Validation of HPLC,TLC and Derivative Spectrophotometric Methods for the Analysis of Ezetimibe in the Presence of Alkaline Induced Degradation Products

Reversed phase‐high performance liquid chromatography (RP‐HPLC), thin layer chromatography (TLC) densitometry and first derivative spectrophotometry (1D) techniques are developed and validated as a stability‐indicating assay of ezetimibe in the presence of alkaline induced degradation products. RP‐HPLC method involves an isocratic elution on a Phenomenex Luna 5μ C₁₈ column using acetonitrile: water: glacial acetic acid (50:50:0.1 v/v/v) as a mobile phase at a flow rate of 1.5 mL/min. and a UV detector at 235 nm. TLC densitometric method is based on the difference in Rf‐values between the intact drug and its degradation products on aluminum‐packed silica gel 60 F₂₅₄ TLC plates as stationary phase with isopropanol: ammonia 33% (9:1 v/v) as a developing mobile phase. On the fluorescent plates, the spots were located by fluorescence quenching and the densitometric analysis was carried out at 250 nm. Derivative spectrophotometry, the zero‐crossing method, ezetimibe was determined using first derivative at 261 nm in the presence of its degradation products. Calibration graphs of the three suggested methods are linear in the concentration ranges 1–10 mcg/mL, 0.1–1 mg/mL and 1–16 mcg/mL with a mean percentage accuracy of 99.05 ± 0.54%, 99.46 ± 0.63% and 99.24 ± 0.82% of bulk powder, respectively. The three proposed methods were successfully applied for the determination of ezetimibe in raw material and pharmaceutical dosage form; the results were statistically analyzed and compared with those obtained by the reported method. Validation parameters were determined for linearity, accuracy and precision; selectivity and robustness and were assessed by applying the standard addition technique.     

Simultaneous determination of benzydamine hydrochloride and five impurities in an oral collutory as a pharmaceutical formulation by high-performance liquid chromatography

A reversed-phase high-performance liquid chromatographic method for the determination of benzydamine hydrochloride and its impurities 3-dimethylaminopropyl 2-benzylaminobenzoate, 3-dimethylaminopropyl-2-aminobenzoate,1-benzyl-1H-indazol-3-ol, 1-benzyl-2-(3-dimethylaminopropyl)-1,2-dihydro-3H-indazol-3-one, and 1-benzyl-3-(3-(3-dimethylaminopropyl)-3-methylamino)propoxy-(1)H-indazole in a collutory formulation is developed. The separation is carried out on a Gemini C(18) (250 × 4.6 mm, 5 μm) column using acetonitrile-methanol-ammonium carbonate buffer (10 mM; pH 10.5) (37.5:37.5:25, v/v/v) as mobile phase at a flow rate of 1.0 mL/min, column temperature 30°C, and UV detection at 218 nm. Famotidine is used as an internal standard. The total run-time is less than 15 min. The analytical curves present coefficients of correlation greater than 0.99, and detection limits are calculated for all analytes. Excellent accuracy and precision are obtained for benzydamine hydrochloride. Recoveries vary from 98.25 to 102.8%, and intra- and inter-day precisions, calculated as the percent relative standard deviation, are lower than 2.2%. Specificity and robustness for benzydamine hydrochloride are also determined. The method allows the quantitative determination of benzydamine hydrochloride and its impurities, and it is suitable for routine analysis in quality control laboratories.     

Simultaneous Determination of Hydrochlorothiazide and Propranolol Hydrochloride in Tablets by High-Performance Liquid Chromatography

Abstract

A simple and stability indicating HPLC procedure is described for the simultaneous determination of hydrochlorothiazide and propranolol hydrochloride in tablet formulations. Potential degradation products of both drugs and synthesis impurities of hydrochlorothiazide were separated, making the determination stability indicating for both drugs and selective for hydrochlorothiazide. All compounds were chromatographed on a cyanopropylsilane column, eluted with a 15:85 mixture of acetonitrile: 0.05 M ammonium phosphate (pH 3.0) and detected at 290 m. Excellent interlaboratory precision and recovery data were obtained. Linearity studies were carried out using peak area measurements. Detector response to the concentration of each drug was confirmed. The method was applied to dosage forms containing 25 mg of hydrochlorothiazide and 40 or 80 mg of propranolol hydrochloride.     

Stability-indicating method for the determination of clorazepate dipotassium-I. Via its final degradation products

A sensitive spectrophotometric procedure is described for the determination of 1,4-benzodiazepine (clorazepate dipotassium) in the presence of its degradation products. The procedure is based on acid hydrolysis of clorazepate dipotassium to yield its final degradation products viz., 2-amino-5-chlorobenzophenone and glycine. The amino-chlorobenzophrenone is extracted from the neutralized hydrolysate with diethyl ether, the extract is evaporated, the residue is dissolved in methanol and its absorbance measured at about 240 nm or 380 nm. Glycine, left in the aqueous layer after etherial extraction of aminochlorobenzophenone, is treated with ninhydrin reagent in the presence of pyridine and the bluish violet colour formed is measured at about 560 nm. The suggested procedures determine 20–100 mg of clorazepate dipotassium via its degradation products aminochlorobenzophenone and glycine with mean accuracies of 100.0 ± 0.5% at 560 nm, 100.2 ± 0.6% at 380 nm and 99.8 ± 0.5%. The suggested procedures are suitable for stability-testing of clorazepate dipotassium in bulk powder and in pharmaceutical preparations.     

Stability-indicating methods for determining omeprazole and octylonium bromide in the presence of their degradation products.

Four stability-indicating assays were developed for determining omeprazole and octylonium bromide. Omeprazole is photodegraded and estimated in the presence of its degradation products sulphenamide (I) and benzimidazole sulphide (II) by 2 methods. The first method depends on use of first-, second-, and third-derivative spectrophotometry at 290.4, 320.6, and 311.6 nm, respectively. The second method is based on applying the charge-transfer technique with chloranil as pi acceptor to form a complex with omeprazole, the absorbance of which is measured at 377 nm. These methods determine omeprazole in concentration ranges of 5-20 micrograms/mL by first-, second-, and third-derivative spectrophotometry and 10-50 micrograms/mL by charge-transfer complexation with mean accuracies of 99.92 +/- 0.73, 99.71 +/- 1.02, 99.64 +/- 0.66, and 100.24 +/- 0.81%, respectively. Octylonium bromide is determined by a densitometric method using thin-layer chromatography in the presence of its degradation products p-[2-(n-octyoxy)benzoyl]-aminobenzoic acid (III) and diethyl-(2-hydroxyethyl)-methyl ammonium bromide (IV) without any interferences. Alternatively, octylonium bromide is evaluated by a colorimetric method using the acid dye rose bengal. The ion pair formed is extracted in chloroform at pH 4, and its absorbance is measured at 562 nm. These methods determine octylonium bromide in the presence of its degradation products in concentration ranges of 0.1-0.5 microgram/microL by densitometry and 4.5-22.5 micrograms/mL by colorimetry, with mean accuracies of 100.21 +/- 0.93 and 99.73 +/- 0.89%, respectively. The suggested methods were used to determine drugs in bulk powder, laboratory-prepared mixtures, and pharmaceutical dosage forms. Results were compared statistically with those obtained with reference methods.     

Photodegradation Kinetics of Fexofenadine Hydrochloride Using a LC Method

The kinetics of photodegradation of the antihistamine fexofenadine hydrochloride using a stability-indicating high performance liquid chromatography (HPLC) method is demonstrated. The degradation was carried out in methanol and in water solutions, prepared from coated tablets, in quartz cells under UV light at 254 nm. The kinetics parameters of order of reaction and the rate constants of the degradation were determined for both solvents. The degradation process of fexofenadine hydrochloride in solutions can be described by second-order kinetics under the experimental conditions used in this study. The obtained results show that the HPLC method is satisfactory in the determination of the kinetics of degradation of fexofenadine hydrochloride in the presence of its photolytic degradation products.     

Colorimetric and Bromometric Determination of Pirbuterol Hydrochloride

Abstract

Two proposed methods are reported for the quantitation of pirbuterol hydrochloride, namely, (i) colorimetric and (ii) titrimetric methods. The colorimetric method is based on coupling betweem diazotized sulphanilamide and pirbuterol hydrochloride. Under the optimum conditions studied, the coupling product exhibits a maximum at 440 nm. Linear relation between absorbance, A, and concentration of pirbuterol hydrochloride is in the range 5–40 μgml^?1. The mean percentage obtained for capsules (Exirel^R ?15 mg) was 100.8 ± 0.7 whereas mean percentage recovery obtained for the authentic drug was 100.5 ± 0.8.

The titrimetric procedure involves bromination of authentic pirbuterol in acid medium and residual titration of excess bromine. The stoichiometry of the reaction was investigated and infra-red analysis, of the bromoderivative was carried out. When applied to capsules the bromometric method gave mean percentage of 100.18 ± 2.25.     

Simultaneous Determination of Levomepromazine Hydrochloride and Its Sulfoxide by UV‐Derivative Spectrophotometry and Bivariate Calibration Method

Abstract

Two spectrophotometric methods are proposed for the simultaneous quantification of levomepromazine hydrochloride (LV) and its main degradation product levomepromazine sulfoxide (LV‐SO). One of them is based on the first order derivative spectra generated by the Savitzky‐Golay algorithm (third‐order polynomial degree, Δλ=10 nm). Determination of levomepromazine hydrochloride and its sulfoxide was realized by measurements of amplitudes of derivative spectra at 332 nm and 278 nm, respectively. The Beer law was obeyed in the concentration range 1.5–50 µg/mL for LV and 2.5–50 µg/mL for LV‐SO. The second of the proposed methods utilized the bivariate calibration algorithm. The determination was performed at 302 nm for levomepromazine and at 334 nm for sulfoxide. The elaborated methods allowed determination of LV in the concentration range 1.0–25 µg/mL while LV‐SO was determined in the concentration range 2.0–50 µg/mL.     

Simple chromatographic detection modes for antitumor agent and its degradants

Degradation of active ingredients is common during the production, transportation, and storage of the pharmaceutical preparations. The resulted degradation products can affect the pharmaceuticals’ therapeutic effect. Also, they may have some toxic properties that make them have deleterious effects on patients. Nifuroxazide, antitumor, antimetastasis, and antidiarrheal agent, has been detected in pharmaceutical formulation by two sensitive, selective, and cheap methods. The first method was densitometric thin-layer chromatography technique. The compound was detected in the presence of its degradation products without any interference. Limits of quantification and detection values were 200 and 94.3?ng/band, respectively. The method was linear in the range 0.2–12?µg/band with mean recovery% ±relative standard deviation (RSD)%?=?99.97%?±?1.414. The second method was developed using simple high-performance liquid chromatography technique. The method was successfully able to separate the proposed compound from its degradation forms in the presence of pentoxiftylline as an internal standard without any interference in less than 5?min. The method also detected nifuroxazide degradation products down to 500?ng/mL. Both methods were statistically compared to a reported method with no significant difference in performance.     

Simultaneous Determination of Losartan Potassium, Atenolol and Hydrochlorothiazide in Pharmaceutical Preparations by Stability-Indicating UPLC

A stability-indicating UPLC method was developed for the simultaneous quantitative determination of losartan potassium, atenolol, and hydrochlorothiazide in pharmaceutical dosage forms in the presence of degradation products. The separation was achieved on a simple isocratic method (water: acetonitrile: triethyl amine: ortho phosphoric acid (60:40:0.1:0.1, v/v) at 0.7 mL min^?1, a detection wavelength of 225 nm). The retention times of losartan potassium, atenolol, and hydrochlorothiazide were 2.3, 0.6 and 0.9 min. The total runtime was 3 min. Losartan potassium, atenolol, and hydrochlorothiazide were subjected to different ICH prescribed stress conditions. The method was validated with respect to linearity, accuracy, precision, robustness and ruggedness.     

LC Method for Studies on the Stability of Sibutramine in Soft Gelatin Capsules

A sensitive and rapid liquid chromatographic method was successfully developed and validated for the determination of sibutramine hydrochloride in bulk and capsules. Sibutramine in the presence of its degradation products was analyzed using UV detection at 225 nm. Chromatography was performed on a reversed-phase C₈ (150 × 4.0 mm I.D., 5 μm) analytical column under isocratic conditions. The mobile phase was composed of acetonitrile:water (aqueous phase containing 0.3% triethylamine and pH adjusted to 7.0) (75:25, v/v) at a flow-rate of 1.1 mL min⁻¹. No chromatographic interference was found during the analysis. Light was the stress condition which most contributed to sibutramine degradation. The method showed a linear response (r > 0.999) from 30 to 90 μg mL⁻¹. The mean recovery for capsules was 101.2%. Inter-day assays showed relative standard deviations of 0.42 and 1.62% for bulk and capsules, respectively. The developed method is able to separate sibutramine from its major degradation products and it may be used in the quality control of this active pharmaceutical ingredient in both bulk and capsules.

     

Synthesis and antitumor activity of novel pyridazinone derivatives containing 1,3,4-thiadiazole moiety

Abstract

A series of novel pyridazinone derivatives containing the 1,3,4-thiadiazole moiety were synthesized and characterized by ¹H NMR, 13C NMR, spectroscopies HRMS and IR. Among them, the structure of compound 5c (2-(Tert-butyl)?4-chloro-5-((5-((2-ethylphenyl)amino)?1,3,4-thiadiazol-2-yl)thio)pyridazin-3(2H)-One) was unambiguously confirmed via single crystal X-ray diffraction analysis. The inhibitory activity of all the target compounds against MGC-803 and Bcap-37 was determined by MTT assay, with doxorubicin (the inhibition rates were 95.5?±?0.4% and 95.7?±?1.0% respectively) as a control. The preliminary results showed that the inhibitory activity of compound 5n (2-(Tert-butyl)?4-chloro-5-((5-((3-fluorophenyl)amino)?1,3,4-thiadiazol-2-yl)thio)pyridazin-3(2H)-One) was superior to the others. The inhibition rates of MGC-803 and Bcap-37 cells were 86.3?±?2.2% and 92.3?±?0.6% at a concentration of 10?μmol/L, respectively. The preliminary structure-activity relationship showed that when the 2-position of the benzene ring was substituted by a methyl group, such as compound 5j (2-(Tert-butyl)?4-chloro-5-((5-((2,3-dimethylphenyl)amino)?1,3,4-thiadiazol-2-yl)thio)pyridazin-3(2H)-One), it exhibited good anticancer activity on MGC-803 cells. Besides, introducing fluorine, chlorine, or trifluoromethyl group onto the benzene ring, such as compound 5?m (2-(Tert-butyl)?4-chloro-5-((5-((4-(trifluoromethoxy)phenyl)amino)?1,3,4-thiadiazol-2-yl)thio)pyridazin-3(2H)-One), displayed good anticancer activity on MGC-803 and Bcap-37 cells.